Khosla Impact

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Rejuvenation Technologies Inc. is a biotechnology company based in Mountain View, California, focused on developing nucleoside-modified telomerase reverse transcriptase messenger RNA to extend telomeres and promote human health. The company's innovative approach involves delivering a telomere extender that encodes telomerase reverse transcriptase, which transiently boosts telomerase activity in cells. This technology aims to enhance the proliferative capacity of cells, potentially addressing age-related diseases and conditions in various medical fields, including hepatic, pulmonary, and immunology. Additionally, Rejuvenation Technologies offers a range of cell therapies that encompass tissue engineering, cell transplants, skin grafts, immunotherapy, and regenerative medicine. Established in 2016, the company is dedicated to advancing solutions in regenerative health.

IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Carver Biosciences is a biotechnology firm specializing in the development of CRISPR/Cas13-based antiviral therapies. The company focuses on creating gene therapies that target RNA viruses, particularly respiratory viruses, at the RNA level. By utilizing the Cas13 technology, Carver aims to destroy these viruses and inhibit their replication. This approach is intended to complement existing vaccination efforts and viral inhibitors, providing patients with alternative treatment options to halt the progression of infections.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Anagenex is a seed stage biotechnology company focused on advancing drug discovery through its innovative platform. The company aims to tackle challenging pharmaceutical targets by utilizing a technology that combines machine learning with DNA-encoded libraries. This approach allows for the rapid analysis of compounds and the generation of extensive data sets, facilitating parallel biochemical experiments. By leveraging proprietary artificial intelligence models, Anagenex enables researchers to efficiently develop new small molecule drugs for medically significant applications.

Ultima Genomics, founded in 2016 and based in Newark, California, specializes in genome-scale sequencing technology aimed at providing analytical services to enterprises. The company employs an innovative approach using an open substrate that creates a large, low-cost reaction surface, allowing for billions of reads without the need for expensive flow cells or complex fluidics. By integrating specialized sequencing hardware with machine learning, Ultima Genomics ensures reproducible and accurate results, enabling clients to obtain genomic reports rapidly and efficiently. This technology not only enhances the scale of genomic information but also significantly reduces the costs associated with sequencing, thereby facilitating advancements in biology and improvements in human health.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing tools for biological automation, focusing on scalable automation solutions for genetic engineering. Volta Labs operates a platform designed for affordable genomic sample preparation, aimed at revolutionizing genomics research. This platform leverages automation and miniaturization technologies to streamline the creation of biological samples. By integrating expertise from engineering, surface chemistry, and molecular biology, Volta Labs enables biotech organizations to automate complex biological workflows, facilitating advancements in genomics and genetic engineering.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Anagenex is a seed stage biotechnology company focused on advancing drug discovery through its innovative platform. The company aims to tackle challenging pharmaceutical targets by utilizing a technology that combines machine learning with DNA-encoded libraries. This approach allows for the rapid analysis of compounds and the generation of extensive data sets, facilitating parallel biochemical experiments. By leveraging proprietary artificial intelligence models, Anagenex enables researchers to efficiently develop new small molecule drugs for medically significant applications.

Pearl Bio is a synthetic biology company focused on advancing the field of biologics and biomaterials. It has developed a platform that incorporates genome engineering, ribosome engineering, and biomanufacturing techniques. This platform allows for the creation of innovative biomaterials and smart biologics, enabling researchers to enhance their understanding of gene function. Pearl Bio's work aims to facilitate the development of products and processes that can be utilized at a commercial scale, ultimately providing new avenues for treating genetic and acquired diseases.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Probably Genetic is dedicated to providing solutions for individuals with rare genetic conditions that are often misdiagnosed as autism spectrum disorder. Recognizing that patients typically endure a lengthy wait of up to seven years for a proper diagnosis, the company aims to alleviate this prolonged uncertainty. They offer educational resources and DNA sequencing tests designed to help individuals and families understand whether there is a genetic basis for their symptoms. By facilitating access to crucial information and testing, Probably Genetic seeks to support those who may otherwise be overlooked by the healthcare system.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.

Loop Genomics is a platform technology for long-read DNA sequencing. Loop Genomics technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing machines. Loop Genomics long-read DNA sequencing technology provides phased sequencing solutions across a diverse repertoire of research and clinical applications. Sequencing of partial rRNA gene sequences results in reduced phylogenetic resolution. Full-length, high-throughput, phased sequencing that covers all 16S variable regions is becoming the gold standard for profiling the microbiome. Achieve the highest resolution microbial community profiling with long-read, next-generation sequencing of the microbiome. Characterizing polymorphisms in HLA genes inside and outside of the protein-coding regions is important for organ transplantation compatibility testing and for strengthening causality association studies. The length of homologous sequences between HLA alleles extends beyond the capabilities of short-read sequencing platforms, resulting in diploid ambiguities and a reliance on imputation. Sequence full-length HLA DNA and/or RNA with phased, high throughput, long-read sequencing that resolves allelic discrimination and diploid ambiguity. Viral genetic variability is a major determinant of viral drug resistance and viral vaccine efficacy. Accurately mapping viral genetic variability is a critical step in choosing the optimal course of therapy and developing efficacious vaccines. Key mutations are typically located throughout long stretches of viral genomes, making the retrieval of critical phased data challenging using short-read sequencing technology. Use phased, high-throughput DNA sequencing technology to map key mutations at the quasi-species level and generate a complete phased map of viral populations.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

BioConsortia, Inc. is an agricultural biotechnology company based in Davis, California, that specializes in the discovery, development, and commercialization of microbial consortia aimed at enhancing agricultural yield. Founded in 2014, the company utilizes a proprietary Advanced Microbial Selection process to identify beneficial microbial consortia that improve crop traits such as fertilizer utilization, growth rates, and resilience to environmental stresses. BioConsortia's products include bio fungicides, bio nematicides, bio insecticides, and biostimulants, which are designed to be applied as seed treatments or soil additives. The company has established research and development facilities in New Zealand and the United States, focusing on harnessing the complex interactions between soil and plant-associated microbes to optimize plant performance and reduce chemical inputs in agriculture.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Ontera Inc. specializes in the development of innovative single molecule detection and genome analysis platforms utilizing biochemistry and silicon nanopore chip technology. The company offers a range of products, including the SAM device, which facilitates the detection and quantification of various targets such as acids, proteins, and small molecules across different applications in plants, animals, and humans. Additionally, Ontera provides the DUO Nano platform for genome mapping, structural variant analysis, epigenetics, and direct strand sequencing. Its solutions cater to diverse sectors, including agriculture, human and animal diagnostics, law enforcement, and drug discovery, among others. Founded in 2011 and headquartered in Santa Cruz, California, Ontera was previously known as Two Pore Guys, Inc. before rebranding in May 2019. The company aims to enhance point-of-care testing and advance the field of third-generation sequencing.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

BioConsortia, Inc. is an agricultural biotechnology company based in Davis, California, that specializes in the discovery, development, and commercialization of microbial consortia aimed at enhancing agricultural yield. Founded in 2014, the company utilizes a proprietary Advanced Microbial Selection process to identify beneficial microbial consortia that improve crop traits such as fertilizer utilization, growth rates, and resilience to environmental stresses. BioConsortia's products include bio fungicides, bio nematicides, bio insecticides, and biostimulants, which are designed to be applied as seed treatments or soil additives. The company has established research and development facilities in New Zealand and the United States, focusing on harnessing the complex interactions between soil and plant-associated microbes to optimize plant performance and reduce chemical inputs in agriculture.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

20n is a biotechnology company that specializes in engineering microbes through advanced algorithms to produce various chemicals. Their technology enables the creation of microbes capable of synthesizing therapeutic compounds, such as Paracetamol, which is traditionally difficult to produce naturally. By leveraging a data mining approach, 20n aims to facilitate the bioproduction of a wide range of valuable molecules. Additionally, the company has developed an open-source platform that allows researchers to predict DNA edits in synthetic biology, providing blueprints for custom fermentation organisms. This platform supports the identification of new molecules and enhances the efficiency of product development in the biotech industry.

BioConsortia, Inc. is an agricultural biotechnology company based in Davis, California, that specializes in the discovery, development, and commercialization of microbial consortia aimed at enhancing agricultural yield. Founded in 2014, the company utilizes a proprietary Advanced Microbial Selection process to identify beneficial microbial consortia that improve crop traits such as fertilizer utilization, growth rates, and resilience to environmental stresses. BioConsortia's products include bio fungicides, bio nematicides, bio insecticides, and biostimulants, which are designed to be applied as seed treatments or soil additives. The company has established research and development facilities in New Zealand and the United States, focusing on harnessing the complex interactions between soil and plant-associated microbes to optimize plant performance and reduce chemical inputs in agriculture.

NewLimit focuses on the development of therapies aimed at treating age-related diseases and enhancing human health span. The company utilizes epigenetic reprogramming techniques and single-cell sequencing to rejuvenate tissues across the body. By addressing significant unmet medical needs, NewLimit aims to reverse aspects of the aging process and improve life expectancy, positioning itself at the forefront of anti-aging technology.